Advantage of Premeal-Injected Insulin Glulisine Compared With Regular Human Insulin in Subjects With Type 1 Diabetes
Open Access
- 1 August 2006
- journal article
- research article
- Published by American Diabetes Association in Diabetes Care
- Vol. 29 (8), 1812-1817
- https://doi.org/10.2337/dc06-0383
Abstract
OBJECTIVE—Insulin glulisine, a rapid-acting insulin analog, provides prandial insulin replacement. In this study, we compared postprandial blood glucose control after pre- and postmeal insulin glulisine with regular human insulin (RHI).Keywords
This publication has 29 references indexed in Scilit:
- Contributions of basal and post-prandial hyperglycaemia to micro- and macrovascular complications in people with type 2 diabetesCurrent Medical Research and Opinion, 2005
- Insulin glulisine: a new rapid-acting insulin analogue for the treatment of diabetesExpert Opinion on Pharmacotherapy, 2005
- The relationship of postprandial glucose to HbA1cDiabetes/Metabolism Research and Reviews, 2004
- Insulin AdministrationDiabetes Care, 2003
- Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)The Lancet, 1998
- Improved mealtime treatment of diabetes mellitus using an insulin analogueClinical Therapeutics, 1997
- Effects of the Short-Acting Insulin Analog [Lys(B28),Pro(B29)] on Postprandial Blood Glucose Control in IDDMDiabetes Care, 1996
- The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes MellitusThe New England Journal of Medicine, 1993
- Action Profile of the Rapid Acting Insulin Analogue: Human Insulin B28AspDiabetic Medicine, 1993
- The Stockholm Diabetes Intervention Study (SDIS): 18 Months' ResultsActa Medica Scandinavica, 1988